palmitic acid N-hydroxysuccinimide ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: palmitic acid N-hydroxysuccinimide ester
• 英文别名: N-Palmitoyloxy-Succinimide>；N-palmitoyloxy-succinimide；(2,5-Dioxopyrrolidin-3-yl) hexadecanoate
• 化学式: C₂₀H₃₅NO₄
• 分子量: 353.502
• InChiKey: LPHJWZFEOCEEID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  25
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 棕榈酰氯 在 三乙胺 作用下， 以 氯仿 、 水 为溶剂， 生成 palmitic acid N-hydroxysuccinimide ester
  参考文献：
  名称：

  COMPOSITION FOR USE AS COSMETIC OR EXTERNAL SKIN PREPARATION

  摘要：

  公开号：

  EP2494953B1

文献信息

• Tuberculosis vaccines comprising antigens expressed during the latent infection phase
  申请人：Statens Serum Institut

  公开号：EP2163255A1

  公开（公告）日：2010-03-17

  The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

  本发明涉及一种免疫原组合物、疫苗或药物组合物，用于预防、增强或治疗由结核复合菌（结核杆菌、牛结核杆菌、非洲结核杆菌、微小结核杆菌）引起的感染。免疫原组合物、疫苗或药物组合物包含融合多肽，融合多肽包含一种或多种来自结核杆菌的饥饿抗原，融合多肽的单位为结核杆菌抗原。此外，本发明还涉及包含本发明融合多肽序列或核酸序列的疫苗与卡介苗同时给药的用途，可以与卡介苗混合给药，也可以在不同部位或途径分别给药，以制备所述免疫原组合物、疫苗或药物组合物。
• Chlamydia trachomatis antigens for vaccine and diagnostic use
  申请人：Statens Serum Institut

  公开号：EP2269636A2

  公开（公告）日：2011-01-05

  The present invention is related to antigens from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.

  本发明与沙眼衣原体的抗原有关，这些抗原能被感染衣原体的人体内的特异性抗体识别，或能诱导这些人的 T 细胞分泌γ-干扰素。T 细胞反应性抗原存在于全细胞裂解液中，经 SDS-PAGE 测定，其表观分子量分别为 5-12、16-20、25-35 和 58-74kDa。据信，本发明的抗原可用于疫苗，也可用作诊断成分。
• Improved tuberculosis vaccines
  申请人：Statens Serum Institut

  公开号：EP2380589A2

  公开（公告）日：2011-10-26

  The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

  本发明涉及一种免疫原组合物、疫苗或药物组合物，用于预防、增强或治疗由结核复合菌（M. tuberculosis、M. bovis、M. africanum、M. microti）引起的感染。免疫原组合物、疫苗或药物组合物包含融合多肽，融合多肽包含一种或多种来自结核杆菌的饥饿抗原，融合多肽的单位为结核杆菌抗原。此外，本发明还涉及包含本发明融合多肽序列或核酸序列的疫苗与卡介苗同时给药的用途，可以与卡介苗混合给药，也可以在不同部位或途径分别给药，以制备所述免疫原组合物、疫苗或药物组合物。
• Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
  申请人：Statens Serum Institut

  公开号：EP2402023A1

  公开（公告）日：2012-01-04

  The present invention teaches a way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease by immunizing with pools of overlapping fragments (synthetic peptides e.g. 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The resulting T-cell response to subdominant epitopes is important for protection against chronic diseases that on their own induces a response focused only towards immunodominant epitopes. The present invention requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to multiple of epitopes of vaccine relevance. For chronic disease controlled by humoral immunity the T helper cell response primed by the peptide mix may be boosted by the full size protein for maximum induction of an antibody response as well.

  本发明传授了一种方法，通过在适当的佐剂中使用所需抗原的重叠片段（如 10-30 mers，2-20 aa 重叠的合成肽）池进行免疫，诱导对任何特定抗原表位的优势和次优势反应的广泛识别，这些抗原对预防或治疗慢性疾病具有重要意义。这样，T 细胞组不仅能识别用于免疫接种的完整分子和慢性感染本身诱导的免疫优势表位，而且还能对一些亚优势表位产生更广泛、更均衡的反应。由此产生的对亚优势表位的 T 细胞反应对于防止慢性疾病非常重要，因为慢性疾病本身诱导的反应只针对免疫优势表位。本发明无需事先了解亚优势表位的精确定位和特性及其在人群中的识别情况，但却扩大了 T 细胞库，从而使疫苗接种后特异性 T 细胞识别的表位总数从几个免疫优势表位增加到多个与疫苗相关的表位。对于由体液免疫控制的慢性疾病，多肽混合物所引发的 T 辅助细胞反应也可通过全尺寸蛋白质来增强，以最大限度地诱导抗体反应。
• M.tuberculosis vaccines
  申请人：Statens Serum Institut

  公开号：US10004793B2

  公开（公告）日：2018-06-26

  The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.

  本发明涉及一种融合蛋白、抗原鸡尾酒和免疫组合物，如预防由毒性分枝杆菌（如结核分枝杆菌、非洲分枝杆菌、牛分枝杆菌、微小分枝杆菌、卡奈特分枝杆菌、羽状分枝杆菌或孟氏分枝杆菌）引起的感染的疫苗。融合蛋白、抗原鸡尾酒和免疫组合物以 ESAT-6 分泌系统 1（ESX-1）分泌的蛋白为基础，是最具免疫优势的结核分枝杆菌（MTB）抗原之一。